1.78

3.26% -0.06

After Hours: 1.81 0.03 +1.69%

Gain Therapeutics Inc (GANX)

Overview News Price History Option Chain Financials Why GANX Down? Discussions Forecast

Gain Therapeutics Inc stock is traded at $1.78, with a volume of 382.89K. It is down -3.26% in the last 24 hours and down -6.56% over the past month. Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Previous Close:

$1.84

Open:

$1.85

24h Volume:

382.89K

Relative Volume:

0.55

Market Cap:

$77.69M

Revenue:

$55,200

Net Income/Loss:

$-21.24M

P/E Ratio:

-3.0246

EPS:

-0.5885

Net Cash Flow:

$-19.37M

1W Performance:

+1.14%

1M Performance:

-6.56%

6M Performance:

-9.18%

1Y Performance:

+2.89%

1-Day Range:

$1.775

$1.8827

1-Week Range:

$1.775

$1.9733

52-Week Range:

$1.53

$4.34

Gain Therapeutics Inc Stock (GANX) Company Profile

Name

Gain Therapeutics Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(301) 500-1556

Address

4800 HAMPDEN LANE, BETHESDA

Employee

Twitter

Next Earnings Date

2026-11-11

Latest SEC Filings

GANX's Discussions on Twitter

Compare GANX vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GANX Gain Therapeutics Inc	1.78	77.69M	55,200	-21.24M	-19.37M	-0.5885
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-06-24	Initiated	ROTH MKM	Buy
Aug-14-24	Resumed	Oppenheimer	Outperform
Apr-12-21	Initiated	BTIG Research	Buy
Apr-12-21	Initiated	Oppenheimer	Outperform

Gain Therapeutics Inc Stock (GANX) Latest News

Sep 18, 2026

Gain Therapeutics Inc (NASDAQ: GANX) Share Price, GANX Stock News, GANX Share Price & Updates - kalkine.ca

Sep 18, 2026

Sep 17, 2026

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference - investingnews.com

Sep 17, 2026

Gain Therapeutics Announces CEO Gene Mack to Participate in ROTH Healthcare Opportunities Conference Panel and One-on-One Meetings - Quiver Quantitative

Sep 17, 2026

Sep 14, 2026

HLS Therapeutics Inc. (TSX:HLS) Gains Momentum as Cardiovascular Growth and Balance Sheet Improvement Support Investor Confidence - kalkine.ca

Sep 14, 2026

Sep 09, 2026

Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of "Moderate Buy" by Analysts - marketbeat.com

Sep 09, 2026

Aug 31, 2026

H.C. Wainwright reiterates Gain Therapeutics stock rating at buy By Investing.com - Investing.com Canada

Aug 31, 2026

H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Aug 31, 2026

Aug 30, 2026

GANX Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates Despite Share SlipAnalyst Drop Coverage - dars.gov.et

Aug 30, 2026

Aug 25, 2026

Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network

Aug 25, 2026

Aug 24, 2026

Gain (GANX) Price: Moves 0.25% Lower to $2.00 in the Latest Reading; Levels: the Session Ends Within the Reported Technical Boundaries under the Current SnapshotFactor Timing - dars.gov.et

Aug 24, 2026

Aug 21, 2026

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Yahoo Finance

Aug 21, 2026

Aug 19, 2026

Gain (GANX) Financial Results: The Bottom-Line Figure Outpaces Its Comparison at the Close; After Results: The Stock Gains 1.97% on the DayEarnings Surprise Stocks - vinanet.vn

Aug 19, 2026

Roth MKM Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Aug 19, 2026

Aug 18, 2026

Gain Therapeutics (GANX) Falls 3.8% to $2.04, Testing Support at $1.94Charm Flow - vinanet.vn

Aug 18, 2026

GSA Capital Partners LLP Purchases Shares of 632,131 Gain Therapeutics, Inc. $GANX - MarketBeat

Aug 18, 2026

Aug 15, 2026

Gain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Aug 15, 2026

Aug 14, 2026

Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Aug 14, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 14, 2026

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance

Aug 14, 2026

Aug 13, 2026